Dbv Technologies SA

dbv-technologies.com

What Do They Do?

Develops Viaskin skin patches intended to treat food allergies in children, along with programs for other immune conditions.

How Do They Make Money?

FY2025 revenue

Who Are Their Customers?

A potential U.S. launch would target children with peanut allergy and their caregivers, allergists and pediatricians, and payers, using digital campaigns, a specialty sales force, non-personal promotion, and account managers.

Do Revenues Turn Into Profits?

No. It lost $146.9M in FY2025.

Operating income, FY2025

−2626% of revenue

▲ +26% (Loss) vs FY2024 (−$116.6M, −2776%)

Net income, FY2025

−2624% of revenue

▲ +29% (Loss) vs FY2024 (−$113.9M, −2712%)

Free cash flow, FY2025

−2173% of revenue

▲ +14% (Loss) vs FY2024 (−$106.8M, −2543%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −53%; vs $1.5M in Q2 FY2025
Net income: ▲ +20% (Loss); vs −$41.9M in Q2 FY2025

Flat. Revenue was $5.6M in FY2025, about the same as the $5.7M of FY2021.

Adds a toddler program The older report described an ongoing peanut-allergy trial for children; the latest report also describes a toddler program, including a supplemental safety study.

Who Do They Compete With?

Competes with Aimmune Therapeutics, Nestlé, Stallergenes Greer, and GlaxoSmithKline

Comments